Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
J Am Acad Dermatol
; 76(3): 432-440.e17, 2017 Mar.
Article
en En
| MEDLINE
| ID: mdl-27889292
ABSTRACT
BACKGROUND:
Safety of biologics is important when treating patients with psoriasis.OBJECTIVE:
We sought to determine the safety of ixekizumab in psoriasis.METHODS:
Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported.RESULTS:
Overall, 4209 patients received ixekizumab (total exposure 6480 patient-years). During the induction period, the IRs of patients experiencing 1 or more treatment-emergent adverse event (AE) were 251 and 236 among ixekizumab- and etanercept-treated patients, respectively, and for serious AEs was 8.3 in both groups. During maintenance, for ixekizumab, the IRs of treatment-emergent AEs and serious AEs were 100.4 and 7.8, respectively. Among all ixekizumab-treated patients from 7 trials, the IR of Candida infections was 2.5. The IRs of treatment-emergent AEs of special interest (including serious infections, malignancies, major adverse cardiovascular events) were comparable for ixekizumab and etanercept during the induction period.LIMITATIONS:
Additional long-term data are required.CONCLUSION:
Ixekizumab had an acceptable safety profile with no unexpected safety findings during ixekizumab maintenance in psoriasis.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Candidiasis
/
Fármacos Dermatológicos
/
Anticuerpos Monoclonales Humanizados
/
Etanercept
/
Neoplasias
Tipo de estudio:
Incidence_studies
/
Prognostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Am Acad Dermatol
Año:
2017
Tipo del documento:
Article